Adrenocortical Carcinoma Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Adrenocortical Carcinoma Treatment Market Trends and Insights

Rising Adoption of Precision Oncology for Rare Endocrine Cancers

The Adrenocortical carcinoma treatment market is moving toward molecular selection rather than uniform treatment use. IGF2 overexpression is present in nearly 90% of tumors, and Wnt and β-catenin pathway disruption appears in up to 54% of cases, which gives researchers repeatable targets across a disease that was once treated in a far more uniform way. A 2025 study in npj Precision Oncology showed that more than 70% of high-SIS patients were predicted responders to immune checkpoint blockade, while more than 65% of low-SIS patients were flagged as biologically resistant.^{[1]W. Hao, “Multi-modal Characterization of Metabolic and Immune Gene Clusters in Adrenocortical Carcinoma Treatment,” npj Precision Oncology, NATURE.COM.} That kind of split matters because it can reduce avoidable trial failure in a disease with very limited patient numbers. The result is that the Adrenocortical carcinoma treatment market is starting to favor developers that can match therapy design with companion testing and more precise enrollment.

Expansion of Orphan Drug Development and Regulatory Incentives

The Adrenocortical carcinoma treatment market continues to benefit from orphan-focused policy support because trial economics in this disease are difficult without exclusivity and development incentives. In both the United States and Europe, orphan frameworks reduce commercial risk for sponsors that would otherwise struggle to justify Phase 2 work in an indication with very low annual incidence. That support is visible in public registries, where small and mid-sized programs continue to move forward in rare endocrine oncology despite limited enrollment pools. The same pattern appears in investigator-led work, where advanced ACC studies continue in national multicenter settings that would be difficult to sustain without regulatory and procedural backing. This has widened the set of companies willing to enter the Adrenocortical carcinoma treatment market even before any new product reaches approval.

Higher Use of Multimodal Therapy in Advanced and Metastatic Disease

The Adrenocortical carcinoma treatment market is gaining support from longer and more complex treatment pathways in advanced disease. The FIRM-ACT standard EDP-M regimen delivered a 23% objective response rate and median overall survival of 14.8 months, while retrospective series reported disease control rates between 30% and 50%.^{[2]N. P. Rowell, “Oncological Management of Adrenocortical Carcinoma, An Update and Critical Review,” Oncology and Therapy, LINK.SPRINGER.COM.} At the same time, mitotane remains difficult to optimize because its CYP3A4 induction can reduce etoposide exposure by nearly 50%, which adds uncertainty to real-world treatment performance. Radiotherapy has become more relevant after a 2025 meta-analysis of 1,338 patients showed lower locoregional recurrence and lower mortality in higher-risk settings after postoperative radiation. These patterns matter because the Adrenocortical carcinoma treatment market expands when patients move through surgery, systemic therapy, radiation, and later-line management instead of relying on a single treatment step.

Genomic Profiling Revealing Actionable Subsets for Trial Enrollment

The Adrenocortical carcinoma treatment market is also changing because genomic testing now supports faster and more selective trial entry. A 2025 prospective study across UK and Italian cohorts validated a 10-gene targeted panel that included CTNNB1, TP53, ZNRF3, RB1, MEN1, CDK4, NF1, ATM, APC, and the TERT promoter, with 5% to 10% variant allele frequency thresholds that fit real-world diagnostic timelines. This makes it easier to identify eligible patients near the time of surgery rather than after they are lost to fragmented referral pathways. The value of that shift became clear when the Phase 2 pembrolizumab plus mitotane study at MD Anderson closed in July 2024 after enrolling only 3 patients. The Adrenocortical carcinoma treatment market is giving a practical edge to companies and centers that build genomic registries before larger combination trials begin.

Very Small Patient Pool Limiting Trial Scale and Commercial Uptake

The Adrenocortical carcinoma treatment market remains constrained by incidence that is usually cited at only 1 to 2 cases per million people each year. Small patient numbers do not just slow trials, they also limit the commercial depth available after launch. That problem was clearly visible when the MD Anderson pembrolizumab plus mitotane study ended after enrolling only 3 patients, even though the clinical rationale for the combination was strong. Limited scale also means that developers must recover research costs across a narrow treated population, which can make pricing and reimbursement more difficult in systems without clear rare-disease funding pathways. For that reason, the Adrenocortical carcinoma treatment market still depends heavily on a small number of tertiary centers that can identify, route, and treat patients consistently.

Severe Toxicity and Monitoring Burden of Current Systemic Therapies

The Adrenocortical carcinoma treatment market is also held back by the burden attached to mitotane use in daily practice. Mitotane requires plasma concentrations in the 14 to 20 mg/L range, and a 2024 tertiary-center audit from Ireland reported a median of 7 months to reach that therapeutic window. The same audit reported abnormal thyroid function in 83% of patients and nausea in 67%, which shows how demanding routine management can be even in specialist settings.^{[3]“Management and Outcomes of Patients Treated with Mitotane for Adrenocortical Carcinoma in a Tertiary Adrenal Tumour Centre in Ireland,” Endocrine Abstracts, ENDOCRINE-ABSTRACTS.ORG.} Label and product information updates in North America and Europe also continue to emphasize CYP3A4 interaction risk, which affects both current care and trial design for combination regimens. This keeps a large part of the Adrenocortical carcinoma treatment market inside hospitals and slows wider movement into outpatient settings.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Treatment Type: Growth Is Shifting Toward Targeted Combinations

In the Adrenocortical carcinoma treatment market, surgery led treatment revenue with a 41.30% share in 2025 because it remains the only curative option for localized disease. Open adrenalectomy still dominates practice, while laparoscopic surgery is limited to selected tumors under 6 cm without local invasion, which keeps procedure volume concentrated in high-volume centers. Chemotherapy remained the next important treatment pillar through EDP-M, but the mitotane effect on etoposide exposure continues to complicate dose planning and treatment consistency. Radiation therapy held a smaller base, yet recent evidence has strengthened its position as an adjunct for locoregional control and selected metastatic settings.

In the Adrenocortical carcinoma treatment market, targeted therapy is set to grow at the fastest 7.23% CAGR through 2031 as new combinations show more activity than older single-agent approaches. The CaboACC Phase 2 dataset reported a 78% disease control rate, an 11% objective response rate, and median progression-free survival of 6 months for cabozantinib in advanced ACC. The camrelizumab plus apatinib combination also stood out with an objective response rate near 50% and median progression-free survival of 12.6 months, which supports VEGFR and PD-1 dual targeting over checkpoint monotherapy.^{[4]Declan Moore, “Therapeutic Strategies for Adrenocortical Carcinoma, Integrating Genomic Insights, Molecular Targeting, and Immunotherapy,” Frontiers in Immunology, FRONTIERSIN.ORG.} Within the adrenocortical carcinoma treatment industry, this suggests that future value creation is more likely to come from combination-led targeted regimens than from incremental use of older cytotoxic backbones.

By Disease Stage: Metastatic Care Carries Higher Revenue Intensity

In the Adrenocortical carcinoma treatment market, localized disease held 55.18% of revenue in 2025 because most newly diagnosed patients enter care through surgery and adjuvant planning. Use of adjuvant mitotane in this setting is becoming more selective, especially after evidence showed no benefit from 2 years of adjuvant treatment in low-to-intermediate risk patients in ADIUVO, even though pooled analyses still support benefit in higher-risk disease. That change is narrowing treatment use in lower-risk patients and concentrating systemic spending on cases with stronger recurrence risk. Locally advanced disease still represents a smaller band, but neoadjuvant EDP-M is gaining importance where tumor shrinkage can make surgery possible in borderline-resectable disease.

In the Adrenocortical carcinoma treatment market, metastatic disease is projected to expand at a 7.54% CAGR through 2031 because each patient typically moves through more lines of care and higher cumulative drug use. This segment combines systemic treatment, local control procedures, salvage therapy, and enrollment into new studies, which produces greater revenue per patient than earlier-stage management. The opening of the CLARITY study in April 2026 and the recruiting Phase 1 DS9051b trial as of February 2026 show that later-line options are broadening in metastatic disease rather than remaining static. Within the adrenocortical carcinoma treatment industry, this is why metastatic care is expected to contribute a disproportionate share of incremental revenue even though the patient count remains limited.

By End User: Hospitals Lead While Specialty Clinics Gain Follow-On Volume

In the Adrenocortical carcinoma treatment market, hospitals accounted for 58.97% of revenue in 2025 because surgery, endocrinology, oncology, and therapeutic drug monitoring are usually managed within the same institution. This concentration is reinforced by the infrastructure needed for cortisol management, open adrenalectomy, adverse-event follow-up, and mitotane level testing. Research and academic institutions also remain important, especially because early-stage programs such as DS9051b and CY-101 are being run through academic and specialist trial sites in Europe. Ambulatory surgical centers and home healthcare continue to hold smaller roles because treatment complexity still limits how far care can move away from specialist supervision.

In the Adrenocortical carcinoma treatment market, specialty clinics are forecast to grow at a 7.84% CAGR through 2031 as stable patients move into endocrine oncology follow-up outside major hospital outpatient units. This trend does not imply lower revenue, because long-term management often includes drug titration, adverse-event review, imaging follow-up, and later-line treatment planning. The shift could accelerate if oral targeted regimens and maintenance-style immunotherapy combinations become more common after current trials mature. The Adrenocortical carcinoma treatment market is therefore developing a two-step care pattern where hospitals capture the initial high-acuity episode and specialty clinics gradually take a larger share of recurring monitoring and maintenance activity.

Geography Analysis

In the Adrenocortical carcinoma treatment market, North America held the largest regional share at 43.38% in 2025 because the region combines strong referral networks, rare-disease reimbursement support, and a high concentration of specialized cancer centers. The United States also remains central to evidence generation, with the National Cancer Institute launching the Phase 2 cabozantinib plus cemiplimab trial in February 2026 with a planned 48-patient cohort that includes adolescents and adults. Canada supports treatment continuity through updated product guidance, and the December 2024 Lysodren monograph revision aligned national labeling with more recent safety and interaction standards. In revenue terms, North America accounted for 43.38% of the Adrenocortical carcinoma treatment market size in 2025 because clinical access and reimbursement are more established here than in most other regions.

In the Adrenocortical carcinoma treatment market, Europe remained the second-largest region, led by Germany, France, the United Kingdom, and Italy. The region still carries much of the foundational treatment evidence because the major European groups helped define standards used in surgery, adjuvant treatment, and systemic care. Lysodren maintained full EMA marketing authorization for advanced, unresectable, metastatic, or relapsed ACC, and the most recent product information update in April 2025 preserved its position as the default systemic option across Europe. Europe also continues to host trial activity and multidisciplinary treatment planning that keep commercial activity concentrated in academic referral hospitals.

In the Adrenocortical carcinoma treatment market, Asia-Pacific is projected to record the fastest regional CAGR at 7.46% through 2031 as cancer infrastructure expands and incidental detection rises with broader imaging use. China has become more visible in clinical evidence after the camrelizumab plus apatinib Phase 2 study reported stronger activity than most single-agent immunotherapy data in previously treated ACC. South Korea is also contributing through the ACCOMPLISH trial of pembrolizumab plus lenvatinib, which remains active in post-platinum disease and is expected to complete primary evaluation in 2027. Japan and India support the regional outlook through broader oncology capacity rather than through a large volume of branded ACC-specific commercial assets.